- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00685256
Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children
Parent Communication Study II - Randomized Controlled Trial of Decision Support vs. Education for Parent Communication of BRCA 1/2 Cancer Genetic Test Results to Children
RATIONALE: A study that evaluates the support of a decision guide used together with genetic counseling may improve communication between mothers undergoing BRCA1/2 testing and their minor-age children.
PURPOSE: This randomized phase III trial is studying standard genetic counseling given together with a decision guide to see how well it works compared with genetic counseling alone in improving communication between mothers undergoing BRCA1/2 testing and their minor-age children.
Studienübersicht
Status
Detaillierte Beschreibung
OBJECTIVES:
Primary
- To evaluate the efficacy of a decision support intervention delivered in conjunction with standard genetic counseling compared to standard genetic counseling alone in improving communication between mothers undergoing BRCA1/2 testing and their minor-age children.
Secondary
- To understand the mechanisms by which decision support impacts on decision outcomes.
- To identify mothers who are most and least likely to benefit from decision support.
- To explore the potential impact of decision support on disclosure and parent-child psychosocial well-being.
OUTLINE: This is a multicenter study. Mothers are stratified according to their child's age (< 13 vs ≥ 13 years old), child's gender (female vs male), and trial site. Mothers are randomized to 1 of 2 arms.
- Arm I (standard genetic counseling with communication aid): Mothers undergo standard pre-test genetic counseling and provide a blood sample for mutation analysis. Mothers also receive a copy of "My Children, My Test Results," a detailed decision guide developed to promote quality and informed decision making and outcomes, and provide support to mothers regardless of whether or not they choose to communicate their BRCA1/2 test results to their children.
- Arm II (standard genetic counseling alone): Mothers undergo standard pre-test genetic counseling and provide a blood sample for mutation analysis. Mothers also receive a copy of "Genetic Testing for Breast and Ovarian Cancer Risk: It's Your Choice" containing information regarding family history of breast and ovarian cancer risks, BRCA1/2 genes, risks and benefits of genetic testing, medical management options for carriers, and considerations including family communication.
All mothers complete extensive family history assessments during their baseline interviews and disclose if they have been diagnosed with cancer, length and type of treatments, and the number of other relatives with a history of cancer. Mothers are assessed at baseline (pre-test genetic counseling), post-genetic counseling after learning test results, and at 1 and 6 months post-genetic counseling by a 30-45 minute multi-item and multi-scale self-report telephone survey. Genetic testing results are also submitted to this study. The frequency (number), intensity (length in minutes), and content of participant-initiated telephone contacts to genetic counselors to assess intervention reactivity; participants' self-reported use of educational guides; and their satisfaction with the intervention will be assessed.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
District of Columbia
-
Washington, D.C., District of Columbia, Vereinigte Staaten, 20007
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02115
- Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
DISEASE CHARACTERISTICS:
- Mothers self-identified as primary caregivers to minor-age children (ages 8-21 years-old)
- Mothers must be undergoing genetic counseling and have provided a blood sample for analysis for BRCA1/2 mutations
- Mothers must have resided in the same home as the child(ren) for the past 6 months and intend to continue to reside with the child(ren) for the next 6 months
PATIENT CHARACTERISTICS:
- At least 21 years old (mothers)
- No serious mental illness (e.g., cognitive and psychotic disorders) or developmental disability that would limit participation or preclude informed consent
- Must be able to adequately understand, speak, and read English
- Must have ready and consistent access to a telephone
PRIOR CONCURRENT THERAPY:
- Not specified
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: Zufällig
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Self-reported outcomes at 1-and 6-months
Zeitfenster: 6 months
|
6 months
|
Decision conflict, as assessed by the Decisional Conflict Scale
Zeitfenster: 6 months
|
6 months
|
Parents' decision satisfaction with their communication decision, as assessed by the Satisfaction With Decision Scale
Zeitfenster: 6 months
|
6 months
|
Decision quality
Zeitfenster: 6 months
|
6 months
|
Disclosure of genetic testing results by parents
Zeitfenster: 6 months
|
6 months
|
Child-rearing alliance between parents, as measured by the Parenting Alliance Measure at baseline, after learning test results, and at 1 and 6 months after genetic counseling
Zeitfenster: 6 months
|
6 months
|
Parent-child communication, as assessed by the Parent-Adolescent Communication Scale at baseline, after learning test results, and at 1 and 6 months after genetic counseling
Zeitfenster: 6 months
|
6 months
|
Family functioning, as assessed by the Family Relationship Index at baseline, after learning test results, and at 1 and 6 months after genetic counseling
Zeitfenster: 6 months
|
6 months
|
Children's stress and worry, as assessed by the Child Behavior Checklist at baseline, after learning test results, and at 1 and 6 months after genetic counseling
Zeitfenster: 6 months
|
6 months
|
Parents' knowledge and awareness of the advantages and disadvantages of disclosing maternal BRCA1/2 test results to their children
Zeitfenster: 6 months
|
6 months
|
Parents' preferences and values regarding family communication of genetic test results
Zeitfenster: 6 months
|
6 months
|
Decision self-efficacy, as assessed by the Decision Self-Efficacy Scale
Zeitfenster: 6 months
|
6 months
|
Cognitive appraisals
Zeitfenster: 6 months
|
6 months
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Kenneth Tercyak, PhD, Lombardi Comprehensive Cancer Center
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CDR0000592726
- P30CA051008 (US NIH Stipendium/Vertrag)
- R01HG002686 (US NIH Stipendium/Vertrag)
- GUMC-2007-444
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Brustkrebs
-
Novartis PharmaceuticalsAbgeschlossenMetastasierter Brustkrebs (MBC) | Locally Advance Breast Cancer (LABC)Vereinigtes Königreich, Spanien
-
BioNTech SESeventh Framework ProgrammeAbgeschlossenBrustkrebs (Triple Negative Breast Cancer (TNBC))Schweden, Deutschland
-
Filipa Lynce, MDAstraZeneca; Daiichi Sankyo, Inc.RekrutierungBrustkrebs | HER2-positiver Brustkrebs | Invasiver Brustkrebs | Entzündlicher Brustkrebs Stadium III | HER2 Low Breast AdenokarzinomVereinigte Staaten
Klinische Studien zur counseling intervention
-
US Department of Veterans AffairsAbgeschlossenDrogenmissbrauch | Doppelte DiagnoseVereinigte Staaten
-
Temple UniversityUnbekanntSitzende Lebensweise | Zigaretten rauchenVereinigte Staaten
-
Hacettepe UniversityAbgeschlossenTyp 2 DiabetesTruthahn
-
Texas Christian UniversityAktiv, nicht rekrutierendMapping-Ansätze zur Vorbereitung des Implementierungstransfers | Behandlungsbereitschaft und EinführungsprogrammVereinigte Staaten
-
Makerere UniversityMinistry of Health, Uganda; Rakai Health Sciences ProjectAktiv, nicht rekrutierend
-
University of California, San DiegoKenya Ministry of Health; Population Council KenyaRekrutierungGewalt in der Partnerschaft | Reproduktiver ZwangKenia
-
University of California, Los AngelesUniversity of California, San Diego; California HIV/AIDS Research Program; Los... und andere MitarbeiterAbgeschlossenHIV-PräventionVereinigte Staaten
-
University of FloridaAbgeschlossenEmpfindlichkeitVereinigte Staaten
-
Case Western Reserve UniversityAmerican UniversityNoch keine RekrutierungErnährung, gesund
-
Thomas Jefferson UniversityRekrutierungProstatakarzinomVereinigte Staaten